Scientists have made a breakthrough in the fight against prostate cancerResearchers have discovered a method that allows "deactivating" genes responsible for the development of prostate cancer. This discovery could become an important step in developing n

Breakthrough in prostate cancer treatment: University of Michigan scientists have created an innovative drug that blocks genetic mechanisms of the tumor. Revolutionary research published in the prestigious journal Nature Genetics.

The study showed that prostate cancer cells critically depend on specific DNA regions - enhancers, functioning as molecular "switches" for tumor growth. The scientific team identified the most important chemical mark of these enhancers - H2BNTac acetylation, and also identified the enzymes p300 and CBP responsible for activating this process.

Based on this fundamental discovery, researchers developed the drug CBPD-409, which specifically destroys the enzymes p300 and CBP. By destroying them, the drug eliminates the H2BNTac mark, which leads to suppression of androgen receptor activity - key stimulators of tumor growth.

During laboratory tests on cell cultures and animal models, the new drug effectively stopped the development of even forms of prostate cancer resistant to standard therapy and contributed to tumor regression without pronounced side effects.

The study authors emphasize that the developed method opens up prospects for a fundamentally new direction of therapy - targeted degradation of proteins that control malignant processes. Scientists believe that this approach could become the basis for treating the most aggressive and therapeutically resistant forms of the disease.